The NINDS Small Business Program provides support to small businesses to develop products addressing unmet clinical and research needs.
Here we present nonconfidential company information about a subset of awardees ready to attract third-party collaborators and investors.
4E Therapeutics, delivering innovative medicines for pain
Aquilus Pharmaceuticals is a biotech company focused on the treatment and management of amyotrophic lateral sclerosis (ALS), neuropathic pain and other neurological disorders.
Dignify Therapeutics, Restoring control of bowel and bladder dysfunction.
Eysz is building an AI-based software platform that uses eye-movement data as input to identify patterns associated with consciousness, cognition, and mood to help doctors and pharma companies measure disease progression and treatment outcomes for neurological disorders starting with epilepsy.
Eysz Executive Summary(pdf, 1092 KB)
Great Lakes NeuroTechnologies, Pioneering remote patient monitoring for Parkinson’s disease and other movement disorders.
Kannalife Sciences, Inc., a pioneering biotech company dedicated to developing small molecule therapeutics targeting inflammation.
NuvOx Therapeutics, Mobilizing Oxygen, Transforming Lives.
Palm Therapeutics is leveraging a proprietary drug discovery platform to develop first-in-class cancer therapies.
PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders including stroke and ALS.
Plumeria Therapeutics, Inc. is a pain therapeutic company developing a novel, non-opioid drug guided by a companion diagnostic.
Rebion is commercializing a breakthrough diagnostic platform technology to definitively identify life-altering conditions that manifest from functional impairments in the brain, including lazy eye and traumatic brain injury.
Rebion Executive Summary(pdf, 1963 KB)
Sinopia Biosciences is an AI/machine learning drug discovery company advancing novel therapeutics in neurology, oncology, and rare diseases, with a first-in-class small molecule for Parkinson’s disease.
SNJ Pharma’s SNJ101, the first plasmin-independent thrombolytic agent, aims to revolutionize the treatment of ischemic diseases by addressing the bleeding complications associated with current thrombolytic therapies, providing a therapeutic option for over 200 million patients.
South Rampart Pharma is committed to improving the lives of people suffering from acute, neuropathic and chronic pain by developing a new class of non-opioid pain medicines that do not have the toxicities found in current over the counter and prescription medicines.